Should Weakness in Guizhou Xinbang Pharmaceutical Co., Ltd.'s (SZSE:002390) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Simply Wall StMar 24 23:26 ET

Guizhou Xinbang Pharmaceutical's subsidiary is embroiled in a bribery scandal; what is the impact?

① Company personnel stated that this matter currently has no impact on the company's operation, and the subsidiary mainly engages in in-hospital pharmaceutical wholesale. Even if penalized later, it will not involve qualification issues. ② Industry experts believe that the short-term impact is significant, while the long-term impact is minimal. In the short term, the principal company may be listed as untrustworthy due to the crime of unit bribery, which would exclude it from the bidding procurement of local hospitals in Guizhou for a period. However, in the long term, since it is not a quality issue, there are opportunities for repair.

cls.cnMar 4 09:08 ET

Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the

① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.

cls.cnMar 2 21:09 ET

Investors Three-year Losses Continue as Guizhou Xinbang Pharmaceutical (SZSE:002390) Dips a Further 6.3% This Week, Earnings Continue to Decline

Simply Wall StFeb 18 19:07 ET

Guizhou Xinbang Pharmaceutical (002390.SZ): Currently, the processing capacity for Traditional Chinese Medicine decoction pieces is 6,000 tons per year, with sufficient capacity.

On February 14, Gelonghui reported that Guizhou Xinbang Pharmaceutical (002390.SZ) stated on the investor interaction platform that the company currently has a processing capacity of 6,000 tons/year for Traditional Chinese Medicine pieces, which is sufficient to meet current and short-term market demand. In the future, the company will increase the processing capacity of Traditional Chinese Medicine pieces through optimizing and adjusting the existing production workshops or expanding, in order to provide adequate support for the market.

Gelonghui FinanceFeb 14 02:43 ET

Unpleasant Surprises Could Be In Store For Guizhou Xinbang Pharmaceutical Co., Ltd.'s (SZSE:002390) Shares

Simply Wall StJan 27 20:08 ET